Craft

Advanced
MyoKardia

MyoKardia

MyoKardia Summary

Company Summary

Overview
MyoKardia is a company that discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Type
Subsidiary
Status
Closed
Founded
2012
HQ
South San Francisco, CA, US | view all locations
Website
http://www.myokardia.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Tassos Gianakakos

    Tassos Gianakakos, Chief Executive Officer, Director

  • William Fairey

    William Fairey, Executive Vice President, Chief Commercial Officer

    • Bob McDowell

      Bob McDowell, Chief Scientific Officer

    • Jake Bauer

      Jake Bauer, Chief Business Officer

    Operating MetricsView all

    Patents Pending (Foreign)

    35
    41.7%

    FY, 2018

    Patents Pending (US)

    1
    66.7%

    FY, 2018

    Phase I Trials Products

    1
    50.0%

    FY, 2018

    LocationsView all

    2 locations detected

    • South San Francisco, CA HQ

      United States

      333 Allerton Ave

    • Brisbane, CA

      United States

      1000 Sierra Point Pkwy

    MyoKardia Financials

    Summary Financials

    Net income (Q3, 2020)
    ($84.7M)
    Cash (Q3, 2020)
    $675.5M
    EBIT (Q3, 2020)
    ($85.4M)

    Competitors and Similar Companies

    Compare competitors

    Footer menu

    Product

    Solutions

    Resources

    Company

    © Craft.co 2026
    Share price data provided by IEX